TxCell Completes a E10.5M Second Round and Initiates Clinical Trials

TxCell Completes a E10.5M Second Round and Initiates Clinical Trials

3/5/2008

Sophia Antipolis, March 5th, 2008 – TxCell, a specialty biopharmaceutical firm developing novel cell therapies for autoimmune and chronic inflammatory diseases, today announced that it had raised €10.5 million in a second round of financing. In 2007, the AFSSAPS (the French Agency for Health Product Safety) authorized the company to start its first clinical trial of a Tr1 lymphocyte-based therapy in Crohn’s disease. This round of financing confirms the significant potential of TxCell’s innovative approach and will enable the company to determine the clinical efficacy of treatment with autologous Tr1 cells.

This second round, led by TxCell’s longstanding investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure, will allow the company to progress its development programs on Crohn’s disease (OvasaveTM), rheumatoid arthritis (CellArthrixTM) and a number of orphan diseases.

“This fundraising testifies to the confidence that TxCell’s longstanding investors have placed in our company and confirms the great potential of this cell therapy approach (based on the biological properties of Tr1 regulatory lymphocytes) for the treatment of autoimmune and chronic inflammatory diseases”, commented Frédéric Hammel, CEO of TxCell.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.